This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

EPGL Medical Invents New Cell Regeneration Technology For Eye Disease

IRVINE, Calif., Aug. 7, 2013 /PRNewswire/ -- EP Global Communications, Inc. and EPGL Medical (the Company), (OTC-PINK: EPGL) announced today that Company engineers have invented a new device for the purpose of treating serious eye diseases such as macular degeneration and retinitis pigmentosa. The technology emits low intensity pulse ultrasound into the eye for the purpose of regeneration of damaged cells and to possibly arrest the degeneration of existing healthy cells within the macula and the entire retina.

"The technology has proven to be very effective in recent research.  We now have the ability to use MEMS to put the technology into the micro size environment for contact lenses.  This technology will be incorporated into therapeutic contact lenses which will emit a low, safe dose of the ultrasound energy into the eye on a regular basis for the purpose of slowing or arresting the development of macular degeneration, retinitis pigmentosa and other eye disorders," said David T. Markus, PhD.  "We want to pioneer the area of therapeutic contact lenses and we can see a tremendous market size and need going into the future for this technology."

On Monday August 12, 2013 EPGL Medical will introduce three more advanced technological devices which is has invented and is currently developing as prototypes and for FDA clearance in the near future.

Facts on Macular Degeneration

Macular degeneration is the second-highest cause of irreversible blindness in the world.  Macular degeneration is a leading cause of vision loss in Americans 60 years of age and older.  The number of people living with macular degeneration today is similar to that of those who have all types of cancer. As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050.  Macular degeneration is expensive, and will only become more expensive as the population aged 65 and older increases.  Estimates of the global cost of visual impairment due to age-related macular degeneration is US$343 billion, including US$255 billion in direct health care costs.

About EP Global Communications, Inc. / EPGL MedicalEP Global Communications, Inc. is a medical device manufacturer and marketing company with a world-class team of doctors and scientists on board.  The Company is currently marketing its first FDA cleared device with several additional "smart" medical devices under development.  The Company is the owner of the cutting edge technological platform for medical device development called "Topspin."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,679.57 +1.34 0.01%
S&P 500 2,059.47 +3.32 0.16%
NASDAQ 4,879.1080 +15.7460 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs